{
    "nctId": "NCT05077449",
    "briefTitle": "A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Investigator-assessed progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged \u226518 years and \u226475 years old;\n2. Patient is in the menopausal state\uff1b\n3. Pathologically-confirmed HR positive and Her2 negative Breast Cancer;\n4. Locally advanced stage, recurrence or metastasis breast cancer; 4.1 Disease progression after previous endocrine therapy\uff1b 4.2 One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy;\n5. At least one measurable lesion (based on RECIST v1.1) or only bone metastases;\n6. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;\n7. Adequate organ and marrow function;\n8. Patient of childbearing age must undergo a serum pregnancy test within 14 days before randomization, and the result is negative; patient is willing to use a medically approved high-efficiency contraceptive method during the study period and within 6 months after the last study drug treatment;\n9. Patient with acute toxic reactions caused by previous anti-tumor treatments or surgical operations were alleviated to grade 0 to 1 (NCI-CTCAE v5.0), or to the level specified by the enrollment criteria;\n10. Patient has signed informed consent before any trial related activities.\n\nExclusion Criteria:\n\n1. Patient with visceral crisis, inflammatory breast cancer, or brain metastases, except for patient with stable brain metastases;\n2. Patient had clinically significant pleural effusions, ascites effusions, or pericardial effusions in the 4 weeks before enrollment;\n3. Patient who received prior treatment with mTOR inhibitors, CDK4/6 inhibitors or fulvestrant;\n4. Participation in a prior treatment of major surgery, chemotherapy, radiotherapy, and any anti-tumor treatment within 14 days before enrollment\uff1b\n5. Patient who participated in other clinical trials within 14 days before enrollment or within 5 half-lives of the trial drug, whichever is longer;\n6. Patient used CYP3A4 potent inhibitors or potent inducers within 14 days before enrollment or within 5 half-lives of the drug, whichever is longer;\n7. Patient who used bisphosphonates or RANKL inhibitors within 7 days before enrollment, patient who have started treatment during the study should not change the method of use;\n8. Any other malignant tumor has been diagnosed within 3 years before randomization;\n9. Patient is in the active stage of HBV, HCV or co-infected with HBV, HCV, or Patient with positive HIV antibody;\n10. Patient with severe infection within 4 weeks before enrollment, or unexplained fever\\> 38.5\u2103 during screening/before enrollment;\n11. Patient with heart function impaired or clinically significant heart disease within 6 months before enrollment;\n12. Cerebrovascular accident occurred within 6 months before enrollment, including history of transient ischemic attack or stroke; symptomatic pulmonary embolism;\n13. Inability to swallow, intestinal obstruction or other factors that affect the taking and absorption of the drug;\n14. Patient with a known hypersensitivity to any of the excipients in this study;\n15. A prior history of autologous or allogeneic hematopoietic stem cell transplantation;\n16. A prior history of psychotropic drug abuse or drug use;\n17. Pregnant or breastfeeding;\n18. The researchers considered that there were some cases that were not suitable for inclusion.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}